Drug Trial Radar · NCT00244387
Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa
Last checked: Nov 20, 2026Latest source record: Sep 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
506
Actual
Start
Mar 2004
Primary completion
Jul 2005
Study completion Jul 2005
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Oct 26, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
Summary
As written by the sponsor on the registry.
Male and female patients aged ≥ 30 years with advanced stage idiopathic Parkinson's disease, not well controlled on existing levodopa will take part in a research study at approximately 82 sites in Europe, Israel, South Africa, Australia and new Zealand. The purpose of the study is to evaluate the effectiveness, safety and tolerability of the rotigotine patch (SPM 962) at an individual patient's optimal dose for a period of 4 months Each patient who qualifies and chooses to participate in the study will receive either rotigotine, pramipexole, or placebo at gradually increasing doses over a period of up to 7 weeks, and then maintain their optimal dose for 4 months. The study clinic visits will include a medical history and physical exam, ECG, blood and urine sample collection, completion of various questionnaires, and completion of a diary to record the severity of their Parkinson's symptoms. Patients who complete the study may enroll in an extension trial and receive active study drug.
Conditions
- Parkinson Disease, Idiopathic
Interventions
SPM 962Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Schwarz
Monheim, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.